Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity
A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits tethered through their C8 positions via an inert propanedioxy linker. This symmetric molecule is a highly efficient minor groove interstrand...
Uloženo v:
| Vydáno v: | Journal of medicinal chemistry Ročník 44; číslo 5; s. 737 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.03.2001
|
| Témata: | |
| ISSN: | 0022-2623 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits tethered through their C8 positions via an inert propanedioxy linker. This symmetric molecule is a highly efficient minor groove interstrand DNA cross-linking agent (XL(50) = 0.045 microM) that is 440-fold more potent than melphalan. Thermal denaturation studies show that, after 18 h incubation with calf thymus DNA at a 5:1 DNA/ligand ratio, it increases the T(m) value by 33.6 degrees C, the highest value so far recorded in this assay. The analogous dimer 4 (DSB-120) that lacks substitution/unsaturation at the C2 position elevates melting by only 15.1 degrees C under the same conditions, illustrating the effect of introducing C2-exo-unsaturation which serves to flatten the C-rings and achieve a superior isohelical fit within the DNA minor groove. This behavior is supported by molecular modeling studies which indicate that (i) the PBD units are covalently bonded to guanines on opposite strands to form a cross-link, (ii) 5 has a greater binding energy compared to 4, and (iii) 4 and 5 have equivalent binding sites that span six base pairs. Dimer 5 is significantly more cytotoxic than 4 in a number of human ovarian cancer cell lines (e.g., IC(50) values of 0.0225 nM vs 7.2 nM, respectively, in A2780 cells). Furthermore, it retains full potency in the cisplatin-resistant cell line A2780cisR (0.024 nM), whereas 4 loses activity (0.21 microM) with a resistance factor of 29.2. This may be due to a lower level of inactivation of 5 by intracellular thiol-containing molecules. A dilactam analogue (21) of 5 that lacks the electrophilic N10-C11/N10'-C11' imine moieties has also been synthesized and evaluated. Although unable to interact covalently with DNA, 21 still stabilizes the helix (Delta T(m) = 0.78 degrees C) and has significant cytotoxicity in some cell lines (i.e., IC(50) = 0.57 microM in CH1 cells), presumably exerting its effect through noncovalent interaction with DNA. |
|---|---|
| AbstractList | A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits tethered through their C8 positions via an inert propanedioxy linker. This symmetric molecule is a highly efficient minor groove interstrand DNA cross-linking agent (XL(50) = 0.045 microM) that is 440-fold more potent than melphalan. Thermal denaturation studies show that, after 18 h incubation with calf thymus DNA at a 5:1 DNA/ligand ratio, it increases the T(m) value by 33.6 degrees C, the highest value so far recorded in this assay. The analogous dimer 4 (DSB-120) that lacks substitution/unsaturation at the C2 position elevates melting by only 15.1 degrees C under the same conditions, illustrating the effect of introducing C2-exo-unsaturation which serves to flatten the C-rings and achieve a superior isohelical fit within the DNA minor groove. This behavior is supported by molecular modeling studies which indicate that (i) the PBD units are covalently bonded to guanines on opposite strands to form a cross-link, (ii) 5 has a greater binding energy compared to 4, and (iii) 4 and 5 have equivalent binding sites that span six base pairs. Dimer 5 is significantly more cytotoxic than 4 in a number of human ovarian cancer cell lines (e.g., IC(50) values of 0.0225 nM vs 7.2 nM, respectively, in A2780 cells). Furthermore, it retains full potency in the cisplatin-resistant cell line A2780cisR (0.024 nM), whereas 4 loses activity (0.21 microM) with a resistance factor of 29.2. This may be due to a lower level of inactivation of 5 by intracellular thiol-containing molecules. A dilactam analogue (21) of 5 that lacks the electrophilic N10-C11/N10'-C11' imine moieties has also been synthesized and evaluated. Although unable to interact covalently with DNA, 21 still stabilizes the helix (Delta T(m) = 0.78 degrees C) and has significant cytotoxicity in some cell lines (i.e., IC(50) = 0.57 microM in CH1 cells), presumably exerting its effect through noncovalent interaction with DNA. A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits tethered through their C8 positions via an inert propanedioxy linker. This symmetric molecule is a highly efficient minor groove interstrand DNA cross-linking agent (XL(50) = 0.045 microM) that is 440-fold more potent than melphalan. Thermal denaturation studies show that, after 18 h incubation with calf thymus DNA at a 5:1 DNA/ligand ratio, it increases the T(m) value by 33.6 degrees C, the highest value so far recorded in this assay. The analogous dimer 4 (DSB-120) that lacks substitution/unsaturation at the C2 position elevates melting by only 15.1 degrees C under the same conditions, illustrating the effect of introducing C2-exo-unsaturation which serves to flatten the C-rings and achieve a superior isohelical fit within the DNA minor groove. This behavior is supported by molecular modeling studies which indicate that (i) the PBD units are covalently bonded to guanines on opposite strands to form a cross-link, (ii) 5 has a greater binding energy compared to 4, and (iii) 4 and 5 have equivalent binding sites that span six base pairs. Dimer 5 is significantly more cytotoxic than 4 in a number of human ovarian cancer cell lines (e.g., IC(50) values of 0.0225 nM vs 7.2 nM, respectively, in A2780 cells). Furthermore, it retains full potency in the cisplatin-resistant cell line A2780cisR (0.024 nM), whereas 4 loses activity (0.21 microM) with a resistance factor of 29.2. This may be due to a lower level of inactivation of 5 by intracellular thiol-containing molecules. A dilactam analogue (21) of 5 that lacks the electrophilic N10-C11/N10'-C11' imine moieties has also been synthesized and evaluated. Although unable to interact covalently with DNA, 21 still stabilizes the helix (Delta T(m) = 0.78 degrees C) and has significant cytotoxicity in some cell lines (i.e., IC(50) = 0.57 microM in CH1 cells), presumably exerting its effect through noncovalent interaction with DNA.A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits tethered through their C8 positions via an inert propanedioxy linker. This symmetric molecule is a highly efficient minor groove interstrand DNA cross-linking agent (XL(50) = 0.045 microM) that is 440-fold more potent than melphalan. Thermal denaturation studies show that, after 18 h incubation with calf thymus DNA at a 5:1 DNA/ligand ratio, it increases the T(m) value by 33.6 degrees C, the highest value so far recorded in this assay. The analogous dimer 4 (DSB-120) that lacks substitution/unsaturation at the C2 position elevates melting by only 15.1 degrees C under the same conditions, illustrating the effect of introducing C2-exo-unsaturation which serves to flatten the C-rings and achieve a superior isohelical fit within the DNA minor groove. This behavior is supported by molecular modeling studies which indicate that (i) the PBD units are covalently bonded to guanines on opposite strands to form a cross-link, (ii) 5 has a greater binding energy compared to 4, and (iii) 4 and 5 have equivalent binding sites that span six base pairs. Dimer 5 is significantly more cytotoxic than 4 in a number of human ovarian cancer cell lines (e.g., IC(50) values of 0.0225 nM vs 7.2 nM, respectively, in A2780 cells). Furthermore, it retains full potency in the cisplatin-resistant cell line A2780cisR (0.024 nM), whereas 4 loses activity (0.21 microM) with a resistance factor of 29.2. This may be due to a lower level of inactivation of 5 by intracellular thiol-containing molecules. A dilactam analogue (21) of 5 that lacks the electrophilic N10-C11/N10'-C11' imine moieties has also been synthesized and evaluated. Although unable to interact covalently with DNA, 21 still stabilizes the helix (Delta T(m) = 0.78 degrees C) and has significant cytotoxicity in some cell lines (i.e., IC(50) = 0.57 microM in CH1 cells), presumably exerting its effect through noncovalent interaction with DNA. |
| Author | Howard, P W Jenkins, T C Thurston, D E Hartley, J A Adams, L J Kelland, L R Gregson, S J Brooks, N A |
| Author_xml | – sequence: 1 givenname: S J surname: Gregson fullname: Gregson, S J organization: CRC Gene Targeted Drug Design Research Group, Cancer Research Laboratories, University of Nottingham, University Park, Nottingham NG7 2RD, UK – sequence: 2 givenname: P W surname: Howard fullname: Howard, P W – sequence: 3 givenname: J A surname: Hartley fullname: Hartley, J A – sequence: 4 givenname: N A surname: Brooks fullname: Brooks, N A – sequence: 5 givenname: L J surname: Adams fullname: Adams, L J – sequence: 6 givenname: T C surname: Jenkins fullname: Jenkins, T C – sequence: 7 givenname: L R surname: Kelland fullname: Kelland, L R – sequence: 8 givenname: D E surname: Thurston fullname: Thurston, D E |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11262084$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kL1OwzAcxD0U0Q8YeAHkiakB20mcZKxaviQEC8yV7fzdurh2iN1C-iw8LKWU6U6nn-6kG6Ke8w4QuqDkmhJGb1ZrQijhmeuhASGMJYyztI-GIawIISll6SnqU7pPSZkN0PcMglm4MQ6di8u9D2MsXI1hK-xGROMd9hoL7PwWLG66tvXWS3A7Xxuxg8Y4wLPnSWJchFaoaLaAxQJcxJ8mLvHSLJa2w6C1UeY3Va0PIbHGvRu3wEIaa2J3WGx8PABd9NF_7fHYnaETLWyA86OO0Nvd7ev0IXl6uX-cTp4SkZEyJhXjhNegKp0XrKKKMKULSXWh0iyXGc-EZFCoiuY6B1kCEcBLnUteac6kIGyErv56m9Z_bCDE-doEBdYKB34T5gWvyqrafzdCl0dwI9dQz5vWrEXbzf__ZD9ljHsd |
| CitedBy_id | crossref_primary_10_1016_j_jelechem_2006_05_015 crossref_primary_10_1016_j_bmcl_2009_09_012 crossref_primary_10_1002_adsc_200505261 crossref_primary_10_1021_acs_chemrev_7b00504 crossref_primary_10_1038_s41392_022_00947_7 crossref_primary_10_1002_chem_202501797 crossref_primary_10_1007_s10637_011_9647_z crossref_primary_10_1101_gad_15699211 crossref_primary_10_1002_jhet_5570430441 crossref_primary_10_1016_j_ejmech_2006_10_017 crossref_primary_10_3390_ijms161125971 crossref_primary_10_1016_j_bmcl_2004_08_050 crossref_primary_10_1517_13543776_16_2_165 crossref_primary_10_1517_13543784_2011_573477 crossref_primary_10_4155_fmc_2019_0331 crossref_primary_10_1016_j_bmcl_2005_10_017 crossref_primary_10_1080_00397910802638537 crossref_primary_10_1016_S0040_4020_02_00940_7 crossref_primary_10_3389_fonc_2024_1323366 crossref_primary_10_1093_jac_dkr044 crossref_primary_10_1016_j_bmcl_2005_05_006 crossref_primary_10_1016_j_bmc_2020_115623 crossref_primary_10_1002_ejoc_200400738 crossref_primary_10_1016_j_ejmech_2019_06_044 crossref_primary_10_1002_ange_201510610 crossref_primary_10_1007_s00280_009_1088_4 crossref_primary_10_1517_13543776_14_12_1693 crossref_primary_10_1016_j_bmcl_2018_12_040 crossref_primary_10_1186_s40164_024_00493_8 crossref_primary_10_1016_j_jchromb_2005_04_027 crossref_primary_10_1016_j_ejmech_2005_02_005 crossref_primary_10_3390_dna5010008 crossref_primary_10_1002_chem_202304272 crossref_primary_10_3390_molecules191016737 crossref_primary_10_1016_j_tetlet_2004_02_148 crossref_primary_10_1182_blood_2017_04_779389 crossref_primary_10_1158_1078_0432_CCR_10_2056 crossref_primary_10_1002_anie_201204631 crossref_primary_10_1002_med_20000 crossref_primary_10_1016_j_ejmech_2014_03_018 crossref_primary_10_1016_j_ijantimicag_2007_01_005 crossref_primary_10_1038_sj_tpj_6500465 crossref_primary_10_1016_j_xphs_2018_11_023 crossref_primary_10_1080_147563021000005631 crossref_primary_10_1002_anie_201510610 crossref_primary_10_1016_j_ejca_2005_04_026 crossref_primary_10_1021_jm051199z crossref_primary_10_1016_j_bmcl_2005_03_051 crossref_primary_10_1021_jm020526p crossref_primary_10_3987_COM_03_S_P_69 crossref_primary_10_1016_j_bmc_2008_06_034 crossref_primary_10_1186_s12917_015_0534_2 crossref_primary_10_1021_jm050956q crossref_primary_10_1016_S0223_5234_03_00116_8 crossref_primary_10_1016_j_tetlet_2008_04_006 crossref_primary_10_1124_dmd_116_073031 crossref_primary_10_1002_ange_201204631 crossref_primary_10_1246_cl_2003_512 crossref_primary_10_1016_S0960_894X_03_00436_0 crossref_primary_10_1371_journal_pone_0105021 crossref_primary_10_1016_j_bmcl_2003_12_017 crossref_primary_10_1016_S0960_894X_02_00326_8 crossref_primary_10_1016_j_bmcl_2022_128876 crossref_primary_10_1016_S1470_2045_01_00454_5 crossref_primary_10_1016_S1359_6446_01_01829_3 crossref_primary_10_1208_s12248_010_9225_x crossref_primary_10_1021_ja902986x crossref_primary_10_4161_cc_10_23_18385 crossref_primary_10_1021_jm030897l crossref_primary_10_1002_chin_200124166 crossref_primary_10_1002_ddr_10334 crossref_primary_10_1016_j_bmcl_2025_130095 crossref_primary_10_1002_jcp_28967 crossref_primary_10_1021_ja205395r crossref_primary_10_1002_cmdc_200700328 crossref_primary_10_1158_1078_0432_CCR_08_1315 crossref_primary_10_1016_j_bmcl_2004_02_063 crossref_primary_10_1124_pr_114_009373 crossref_primary_10_1023_B_DRUG_0000026249_97007_60 crossref_primary_10_1038_nrc1587 crossref_primary_10_1016_j_bmcl_2004_08_002 crossref_primary_10_1158_0008_5472_CAN_10_0790 crossref_primary_10_1016_j_tetlet_2004_08_090 crossref_primary_10_1158_0008_5472_CAN_03_2942 crossref_primary_10_1038_sj_bjc_6603853 crossref_primary_10_1158_0008_5472_CAN_03_2941 crossref_primary_10_1016_j_critrevonc_2024_104472 crossref_primary_10_1016_j_bmcl_2019_03_049 crossref_primary_10_1046_j_1432_1033_2003_03663_x crossref_primary_10_3987_COM_11_12207 crossref_primary_10_1016_j_bmc_2004_06_013 crossref_primary_10_1016_j_bmc_2007_08_026 crossref_primary_10_1016_j_bmcl_2006_08_005 crossref_primary_10_1002_cmdc_201402264 crossref_primary_10_1016_j_tetlet_2004_06_112 crossref_primary_10_1021_jm020124h crossref_primary_10_1053_j_gastro_2006_03_016 crossref_primary_10_1016_j_bmc_2008_07_069 crossref_primary_10_1016_S0040_4039_03_00437_4 crossref_primary_10_1158_1078_0432_CCR_12_2529 crossref_primary_10_1016_j_dnarep_2024_103739 crossref_primary_10_1016_j_bmcl_2003_10_050 crossref_primary_10_1016_j_bmcl_2008_01_096 crossref_primary_10_1371_journal_pone_0235483 crossref_primary_10_1016_j_bmcl_2006_10_070 crossref_primary_10_1021_jm0400193 crossref_primary_10_1016_j_ddtec_2018_10_004 crossref_primary_10_1021_bi0479813 crossref_primary_10_1016_S0960_894X_01_00560_1 crossref_primary_10_1371_journal_pone_0152303 crossref_primary_10_3987_REV_10_SR_E_1 crossref_primary_10_1002_ange_201307628 crossref_primary_10_1016_S0960_894X_03_00738_8 crossref_primary_10_1158_0008_5472_CAN_04_1713 crossref_primary_10_1016_S1607_551X_09_70441_3 crossref_primary_10_1016_j_bmc_2003_10_056 crossref_primary_10_1021_bi034313t crossref_primary_10_1016_j_bmcl_2003_08_071 crossref_primary_10_1016_j_ejmech_2025_118114 crossref_primary_10_1016_j_jmb_2024_168618 crossref_primary_10_1002_anie_201307628 crossref_primary_10_1016_j_ejmech_2019_111900 crossref_primary_10_1016_j_ejmech_2019_111866 crossref_primary_10_1016_j_ejps_2018_05_002 crossref_primary_10_1016_S0040_4039_02_01453_3 crossref_primary_10_1002_med_20212 crossref_primary_10_1158_1078_0432_CCR_20_2149 crossref_primary_10_1021_bi0486435 crossref_primary_10_1016_j_bmc_2004_07_045 crossref_primary_10_1007_s00044_023_03177_w crossref_primary_10_1093_nar_gkr122 crossref_primary_10_1016_j_ab_2007_11_018 crossref_primary_10_1016_j_bmc_2005_08_020 crossref_primary_10_1016_j_tetlet_2017_05_020 crossref_primary_10_1016_j_bmc_2005_01_010 crossref_primary_10_3109_10409238_2010_502166 crossref_primary_10_1016_j_tetlet_2008_01_004 crossref_primary_10_1093_jac_dki256 crossref_primary_10_1002_jms_1268 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1021/jm001064n |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | 11262084 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X .GJ .K2 3EH 53G 55A 5GY 5RE 5VS 7~N 9M8 AABXI AAHBH AAYOK ABJNI ABMVS ABOCM ABQRX ABTAH ABUCX ACGFO ACGFS ACJ ACRPL ACS ADHLV ADNMO AEESW AENEX AEYZD AFEFF AFFNX AGXLV AHGAQ ALMA_UNASSIGNED_HOLDINGS ANPPW ANTXH AQSVZ BAANH CGR CS3 CUPRZ CUY CVF DU5 EBS ECM ED~ EIF EJD F5P GGK GNL IH2 IH9 IHE JG~ L7B LG6 MVM NHB NPM P2P ROL TN5 UI2 VF5 VG9 VXZ W1F WH7 XSW YIN YQT YZZ ZE2 ZGI ZY4 7X8 ABBLG ABLBI AGQPQ |
| ID | FETCH-LOGICAL-a408t-92606dec9f57291c02cf7b1f7c345b464ab2e7c915f5eb8e0ae68f5b69f62ba02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 193 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000167257600010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0022-2623 |
| IngestDate | Thu Oct 02 07:10:57 EDT 2025 Wed Feb 19 02:34:04 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a408t-92606dec9f57291c02cf7b1f7c345b464ab2e7c915f5eb8e0ae68f5b69f62ba02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 11262084 |
| PQID | 76989931 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_76989931 pubmed_primary_11262084 |
| PublicationCentury | 2000 |
| PublicationDate | 2001-03-01 |
| PublicationDateYYYYMMDD | 2001-03-01 |
| PublicationDate_xml | – month: 03 year: 2001 text: 2001-03-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of medicinal chemistry |
| PublicationTitleAlternate | J Med Chem |
| PublicationYear | 2001 |
| SSID | ssj0003123 |
| Score | 2.1188166 |
| Snippet | A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 737 |
| SubjectTerms | Antineoplastic Agents - chemical synthesis Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Benzodiazepinones - chemical synthesis Benzodiazepinones - chemistry Benzodiazepinones - pharmacology Cisplatin - pharmacology Cross-Linking Reagents - chemical synthesis Cross-Linking Reagents - chemistry Cross-Linking Reagents - pharmacology DNA - chemistry Drug Design Drug Resistance, Neoplasm Drug Screening Assays, Antitumor Electrophoresis, Agar Gel Heating Humans Models, Molecular Protein Denaturation Pyrroles - chemical synthesis Pyrroles - chemistry Pyrroles - pharmacology Structure-Activity Relationship Tumor Cells, Cultured |
| Title | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/11262084 https://www.proquest.com/docview/76989931 |
| Volume | 44 |
| WOSCitedRecordID | wos000167257600010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7SptBckjR9pW1SHUpOK2LLli1DoYQ8yCXLHlLY2yLLEiRsJXftLHV-S35sR_Ian0oOvfhg5AeaYeaTNPN9AN8QsSqeGE0x-OcUA15GC5Wk1ChcNGvByqySQWwin07FfF7MtuD70AvjyyqHmBgCdeWU3yM_zb3SYZHEP-rf1GtG-bPVjYDGC9hOEMh4L8_nI1d4ErNk4ApnmOUHXiEWn97_Cmuh1P4bV4b8crX3f3-2D7sbXEnOekd4A1vaHsDr80HO7QBOZj1JdTcht2PPVTMhJ2Q20ld3b-HpIhR1TEjTWUSHzR2OkbYiIy84cYZIYt1aL0ndrVbOV2zYR4eu9qhrhK3kYnpGPRFFaMFaayJ9Axfxe77E8yMvO6IDdYW_G_I03Wg4kJ42vAtfrF0bBnSta90fHN527-Dn1eXt-TXdaDhQmUaipQWul7JKq8JwhPGxipgyeRmbHB2Cl2mWypLpXBUxN1yXQkdSZ8LwMitMxkoZsffw0jqrPwIxJa-4iJjM0gJBnhCG4ctSzWLFqzwyh_B1sM8C59YffEir3UOzGCx0CB96Ey_qnspj4RuoWCTST88--xl2xvKzL7BtMDroI3il1u1dszoOrofX6ezmLy6L6Uw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Design%2C+synthesis%2C+and+evaluation+of+a+novel+pyrrolobenzodiazepine+DNA-interactive+agent+with+highly+efficient+cross-linking+ability+and+potent+cytotoxicity&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Gregson%2C+S+J&rft.au=Howard%2C+P+W&rft.au=Hartley%2C+J+A&rft.au=Brooks%2C+N+A&rft.date=2001-03-01&rft.issn=0022-2623&rft.volume=44&rft.issue=5&rft.spage=737&rft_id=info:doi/10.1021%2Fjm001064n&rft_id=info%3Apmid%2F11262084&rft_id=info%3Apmid%2F11262084&rft.externalDocID=11262084 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon |